A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Ichthyosis

Trial ID or NCT#

NCT04697056

Status

not recruiting iconNOT RECRUITING

Purpose

Efficacy and Safety of imsidolimab in Participants with Ichthyosis

Official Title

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ANB019 in the Treatment of Subjects With Ichthyosis

Eligibility Criteria

Ages Eligible for Study: 12 Years to 75 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. - Diagnosis of Ichthyosis - IASI total score ≥ 18, erythema score ≥ 2 - Participant has been using emollient daily for at least 1 week prior to Day 1 and agrees to continue using that same emollient daily at the same frequency throughout the study
Exclusion Criteria:
  1. - A participant with ichthyosis vulgaris, X-linked ichthyosis, or lamellar ichthyosis will be excluded.
View All Criteria
Show Less

Investigator(s)

Joyce Teng, MD, PhD
Joyce Teng, MD, PhD
Dermatologist, Pediatric dermatologist
Professor of Dermatology and, by courtesy, of Pediatrics

Contact us to find out if this trial is right for you.

Contact

SPECTRUM
650-723-0363

View on ClinicalTrials.gov